Entourage Health Stock Forecast & Price Prediction 2026-2027

Algorithmic price targets and analysis for ETRGF based on fundamentals, valuation multiples, and historical data.

$3.32+1.35%
Neutral

Price Target Summary

Bear Case
$2.66
-20.0% from current
Base Case
$6.63
+99.7% from current
Bull Case
$11.93
+259.4% from current

Technical Outlook

52-Week Range Analysis

$1.34$4.80
Current: $3.32
Support Level
$1.69
Resistance Level
$4.45
From 52W High
-30.8%
From 52W Low
+147.8%

Fundamental Analysis

Revenue Growth Projection

Year 1 Projected
$1.39B
Year 2 Projected
$1.63B
Year 3 Projected
$1.85B

Based on +22.0% YoY growth, tapered 20% per year in outer projections.

Valuation vs Peers

Current P/S
14.73x
Sector Median P/S
2.5x
Assessment
Premium to sector

Cash Position

Cash on Hand
$466.9M
Total Debt
$544.0M
Cash Runway
12 mo

Key Metrics

Current Price$3.32
Market Cap$1.74B
P/S Ratio14.73x
Revenue (TTM)$1.14B
Revenue Growth (YoY)+22.0%
Gross Margin23.7%
Cash on Hand$466.9M
Total Debt$544.0M
52W High$4.80
52W Low$1.34

Signal Breakdown

Overall Signal: Neutral
  • Strong revenue growth above 10% YoY
  • Healthy gross margins above 40%
  • Total debt exceeds cash position
  • Elevated P/S ratio relative to sector

Risk Factors

  • Share dilution rate of 16.3% is above average, which may erode shareholder value.

Analyst Summary

Entourage Health (ETRGF) is a LP cannabis company with rapidly growing revenue and a market capitalization of $1.74B. Based on trailing revenue of $1.14B and a P/S ratio of 14.73x, the stock trades at a premium relative to the sector median of 2.5x. Our algorithmic base-case price target of $6.63 implies upside of 99.7% from current levels. The overall signal is neutral, with a mixed fundamental picture. Investors should weigh the 1 identified risk factor before making any investment decision.

Frequently Asked Questions

What is the price target for ETRGF?+
Our algorithmic base-case price target for Entourage Health (ETRGF) is $6.63, with a bear case of $2.66 and a bull case of $11.93. These targets are derived from sector-average and premium P/S multiples applied to projected revenue.
Is ETRGF a buy right now?+
Based on our algorithmic analysis, ETRGF currently carries a neutral signal. Strong revenue growth above 10% YoY. Healthy gross margins above 40%. This is not a buy or sell recommendation — always do your own due diligence.
What is the revenue forecast for Entourage Health?+
Based on the current year-over-year growth rate of +22.0%, we project ETRGF revenue at $1.39B in Year 1, $1.63B in Year 2, and $1.85B in Year 3. Growth rates are tapered in outer years.
What are the risks of investing in ETRGF?+
Share dilution rate of 16.3% is above average, which may erode shareholder value.
How does ETRGF valuation compare to the cannabis sector?+
ETRGF has a trailing P/S ratio of 14.73x compared to the cannabis sector median of 2.5x. The stock premium to sector.

Important Disclaimer

This is not financial advice. Forecasts are algorithmic projections based on historical data and should not be used as the sole basis for investment decisions. Past performance does not guarantee future results. Cannabis stocks carry significant risk including regulatory, market, and operational risks. Always consult with a qualified financial advisor before making investment decisions. Cannabismarketcap does not recommend buying, selling, or holding any security.

← Back to ETRGF OverviewAll Cannabis Stocks